Drug intelligence / Profile preview

insulin human + insulin degludec

Development stage
Unknown
Lead developer
Novo Nordisk
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

This drug is a **combination of human insulin and insulin degludec**. Both are peptide hormones used for managing blood glucose levels in diabetes mellitus. **Human insulin** is a recombinant form of natural human insulin, while **insulin degludec** is a long-acting insulin analog designed for prolonged glucose-lowering effect. Both lower blood glucose by promoting peripheral glucose uptake (mainly in muscle and fat), inhibiting hepatic glucose production, and suppressing lipolysis and proteolysis[1][3][4].\n\n**Mechanism of action:** Both components act as agonists at the insulin receptor. Insulin degludec additionally exhibits a delayed and prolonged absorption phase due to multihexamer formation at the injection site and reversible binding to albumin in circulation, giving it an ultra-long duration of action[1][4].\n\nThis combination is used for the **treatment of diabetes mellitus** (primarily type 1 and type 2 diabetes) in patients who require both a basal (long-acting) component and an additional insulin to mimic physiological insulin activity, or to achieve optimal glycemic control[1][3][4].

02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin human + insulin degludec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin human + insulin degludec.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call